Home
About
Overview
Sharing Data
ORCID
Help
History (24)
Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia.
Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia.
Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia.
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia.
See All 24 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia.
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nat Genet. 2019 02; 51(2):296-307.
View in:
PubMed
subject areas
Acute Disease
Adolescent
Adult
Aged
Animals
Child
Child, Preschool
Chromosomes
Female
Gene Rearrangement
Humans
Infant
Male
Mice
Mice, Inbred C57BL
Middle Aged
Mutation
PAX5 Transcription Factor
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Transcriptome
Young Adult
authors with profiles
Wendy Stock